172 related articles for article (PubMed ID: 33300380)
1. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
Iltar U; Sözel H; Sözel YK; Ataş Ü; Yücel OK; Salim O; Aydin F; Undar L
Leuk Lymphoma; 2021 May; 62(5):1098-1106. PubMed ID: 33300380
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
3. [Low psoas muscle index as independent poor prognostic factor for diffuse large B-cell lymphoma in elderly patients].
Arai K; Mitsuhashi K; Honjo Y; Kurachi M; Komiya Y; Arao T; Sato H
Rinsho Ketsueki; 2022; 63(1):7-13. PubMed ID: 35135956
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Lanic H; Kraut-Tauzia J; Modzelewski R; Clatot F; Mareschal S; Picquenot JM; Stamatoullas A; Leprêtre S; Tilly H; Jardin F
Leuk Lymphoma; 2014 Apr; 55(4):817-23. PubMed ID: 23781925
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.
Niiyama-Uchibori Y; Okamoto H; Miyashita A; Mizuhara K; Kanayama-Kawaji Y; Fujino T; Tsukamoto T; Mizutani S; Shimura Y; Teramukai S; Kuroda J
Hematol Oncol; 2024 Jan; 42(1):e3252. PubMed ID: 38287527
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
Lucijanić M; Korunić RH; Sedinić M; Kušec R; Pejša V
Leuk Lymphoma; 2021 Oct; 62(10):2535-2538. PubMed ID: 33908324
[No Abstract] [Full Text] [Related]
9. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Go SI; Kim HG; Kang MH; Park S; Lee GW
BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
[TBL] [Abstract][Full Text] [Related]
10. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.
Rier HN; Kharagjitsing H; van Rosmalen J; van Vugt J; Westerweel PE; de Jongh E; Kock M; Levin MD
Leuk Lymphoma; 2020 Jul; 61(7):1618-1626. PubMed ID: 32167390
[TBL] [Abstract][Full Text] [Related]
12. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
13. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Nakamura N; Hara T; Shibata Y; Matsumoto T; Nakamura H; Ninomiya S; Kito Y; Kitagawa J; Kanemura N; Goto N; Shiraki M; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
[TBL] [Abstract][Full Text] [Related]
15. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
18. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
Beltran BE; Paredes S; Castro D; Cotrina E; Sotomayor EM; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e551-e557. PubMed ID: 31320254
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.
Chu MP; Lieffers J; Ghosh S; Belch A; Chua NS; Fontaine A; Sangha R; Turner RA; Baracos VE; Sawyer MB
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):298-304. PubMed ID: 27897411
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]